Long-term outcome of staged versus one-stage bilateral thoracoscopic reduction pneumoplasty.
OBJECTIVE
In a prospective non-randomized study, we tested the hypothesis that unilateral reduction pneumoplasty followed by completion of bilateral treatment at the reappearance of symptoms might result in more sustained improvements and better survival than one-stage bilateral treatment.


METHODS
Fifty-nine patients undergoing bilateral thoracoscopic reduction pneumoplasty as a one-stage (n=33) or staged (n=26) procedure were evaluated on. The main indication for staged reduction pneumoplasty was symptom deterioration after unilateral treatment for asymmetric emphysema. Complete clinical assessment was carried out preoperatively and every 6 months postoperatively.


RESULTS
The mean length of follow-up was 34+/-15 months. Interval time between operations in the staged group averaged 15.2 months. There was no inter-group difference in baseline data. Peak improvements in forced expiratory volume in 1 s (FEV(1)), forced vital capacity (FVC) and residual volume (RV) was significantly greater following one-stage bilateral reduction pneumoplasty. In particular, Delta FEV(1) was 0.33+/-0.2 l in the staged group and 0.43+/-0.2 l in the one-stage group (P=0.007). At 48 months, FEV(1), RV and 6-min-walking-test (6MWT) were still significantly improved only in the staged group. Four-year survival was 70% in the staged group and 81% in the one-stage group (Cox-Mantel test, P=not significant).


CONCLUSIONS
Durable physiological improvements and satisfactory survival were achieved in this study for up to 4 years following either staged or one-stage bilateral reduction pneumoplasty using thoracoscopic technique. However, while peak improvements in FEV(1), FVC and RV were significantly greater following one-stage bilateral reduction, long-term improvements in FVC and 6MWT were more stable following a staged procedure. We speculate that sequential unilateral reduction pneumoplasty may reduce the mechanical stress in the lung leading to less steep postoperative deterioration of respiratory function.
Pompeo
Eugenio
E
Department of Thoracic Surgery, Tor Vergata University, Policlinico Tor Vergata, Via Oxford 81, 00133 Rome, Italy. pompeo@med.uniroma2.it
Mineo
Tommaso Claudio
TC
D000368:Aged; D005500:Follow-Up Studies; D005541:Forced Expiratory Volume / Q000502:physiology; D006801:Humans; D007902:Length of Stay; D008168:Lung / Q000098:blood supply* / Q000503:physiopathology / Q000601:surgery*; D008875:Middle Aged; D011446:Prospective Studies; D011656:Pulmonary Emphysema / Q000503:physiopathology / Q000601:surgery; D013510:Pulmonary Surgical Procedures / Q000379:methods* / Q000401:mortality; D012115:Residual Volume / Q000502:physiology; D012384:Rome; D012720:Severity of Illness Index; D016019:Survival Analysis; D013995:Time; D013997:Time Factors; D016896:Treatment Outcome; D014797:Vital Capacity / Q000502:physiology; D016138:Walking / Q000502:physiology